Farther Finance Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.72K Buy
986
+878
+813% +$2.18K ﹤0.01% 5292
2026
Q2
$253 Buy
+108
New +$229 ﹤0.01% 5680
2024
Q3
– Sell
-85
Closed -$99 – 4094
2024
Q2
$99 Buy
+85
New +$100 ﹤0.01% 3599

Other funds holding PLX

Farther Finance Advisors's PLX Position: Q3 2026 in Review

Farther Finance Advisors increased its Protalix BioTherapeutics (PLX) stake by 813% in Q3 2026, buying an estimated $2.18K and bringing the position to 986 shares worth $2.72K. The position accounts for ﹤0.01% of the portfolio, ranked #5292.

Farther Finance Advisors first reported a position in PLX in Q2 2024 and has held it in 3 quarters since. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Farther Finance Advisors held 986 shares of Protalix BioTherapeutics worth $2.72K as of Q3 2026.
  • Farther Finance Advisors bought 878 Protalix BioTherapeutics shares in Q3 2026, an estimated $2.18K.
  • Protalix BioTherapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5292 holding.
  • Farther Finance Advisors first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 3 quarters since.
  • 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.